Voltaren, rectal suppositories 50 mg, 10 pcs.
Manufacturer
Novartis Pharma Stein AG, Switzerland
Compound
1 suppository contains:
Active substances:
diclofenac (in the form of sodium salt) - 50 mg.
Excipients:
solid fat - up to 2 g.
pharmachologic effect
Voltaren is a non-steroidal anti-inflammatory drug (NSAID). It has a pronounced analgesic, anti-inflammatory and antipyretic effect.
The main mechanism of action of diclofenac, established under experimental conditions, is considered to be inhibition of prostaglandin biosynthesis. Prostaglandins play an important role in the genesis of inflammation, pain and fever.
In vitro, diclofenac sodium in concentrations equivalent to those achieved in the treatment of patients does not suppress the biosynthesis of proteoglycans in cartilage tissue. In rheumatic diseases, the anti-inflammatory and analgesic properties of Voltaren provide a clinical effect, characterized by a significant reduction in the severity of such manifestations of diseases as pain at rest and during movement, morning stiffness and swelling of the joints, as well as an improvement in the functional state.
Indications
– inflammatory and degenerative diseases of the musculoskeletal system: rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, spondyloarthritis, osteoarthritis; – diseases of the spine accompanied by pain; – rheumatic diseases of extra-articular soft tissues; – post-traumatic and postoperative pain syndromes, accompanied by inflammation and swelling; – gynecological diseases accompanied by pain and inflammation (for example, primary algodismenorrhea, adnexitis); – as an additional remedy for severe infectious and inflammatory diseases of the ear, nose and throat, which occur with severe pain, for example, pharyngitis, tonsillitis, otitis media. The main treatment of the disease is carried out in accordance with generally accepted principles, incl. with the use of etiotropic therapy. Isolated fever is not an indication for the use of the drug; - migraine attacks.
Contraindications
– proctitis (only for suppositories); – hematopoietic disorders; – children under 14 years of age; – hypersensitivity to diclofenac and any other ingredients of the drug.
The drug is not recommended for use in the third trimester of pregnancy (possible suppression of uterine contractility and premature closure of the ductus arteriosus in the fetus).
Side effects
When assessing the frequency of occurrence of various adverse reactions, the following gradations were used: often - >10%, sometimes - >1-10%, rarely - >0.001-1%, in some cases
- From the digestive system: sometimes - pain in the epigastric region, nausea, vomiting, diarrhea, abdominal cramps, dyspepsia, flatulence, anorexia; rarely - gastrointestinal bleeding (vomiting blood, melena, diarrhea mixed with blood), stomach and intestinal ulcers, accompanied or not accompanied by bleeding or perforation; in some cases - aphthous stomatitis, glossitis, damage to the esophagus, the occurrence of diaphragm-like strictures in the intestine, disorders of the distal colon, such as nonspecific hemorrhagic colitis, exacerbation of ulcerative colitis or Crohn's disease, constipation, pancreatitis; sometimes - increased levels of aminotransferases in the blood serum; rarely - hepatitis, accompanied or not accompanied by jaundice; in some cases - fulminant hepatitis.
From the central nervous system and peripheral nervous system: sometimes - headache, dizziness; rarely - drowsiness; in some cases - sensitivity disorders, including paresthesia, memory disorders, disorientation, insomnia, irritability, convulsions, depression, anxiety, nightmares, tremor, psychotic reactions, aseptic meningitis.
From the senses: in some cases - visual impairment (blurred vision, diplopia), hearing impairment, tinnitus, disturbances in the sense of taste.
From the cardiovascular system: in some cases - palpitations, chest pain, increased blood pressure, worsening congestive heart failure.
Dermatological reactions: sometimes - skin rashes; rarely - urticaria; in some cases - bullous rashes, eczema, erythema multiforme, Stevens-Johnson syndrome, Lyell's syndrome (acute toxic epidermal necrolysis), erythroderma (exfoliative dermatitis), hair loss, photosensitivity reactions; purpura, incl. allergic.
From the urinary system: rarely - swelling; in some cases - acute renal failure, hematuria, proteinuria, interstitial nephritis; nephrotic syndrome; papillary necrosis.
From the hematopoietic system: in some cases - thrombocytopenia, leukopenia, hemolytic anemia, aplastic anemia, agranulocytosis.
Hypersensitivity reactions: rarely - bronchospasm, systemic anaphylactic/anaphylactoid reactions, including hypotension; in some cases - vasculitis, pneumonitis.
Interaction
Voltaren can be prescribed together with oral hypoglycemic drugs and the effectiveness of the latter does not change. However, there are isolated reports of the development in such cases of both hypoglycemia and hyperglycemia, which necessitated the need to change the dose of hypoglycemic drugs during the use of Voltaren.
Caution should be exercised when using NSAIDs less than 24 hours before starting or after stopping methotrexate therapy, because its blood levels (and therefore toxicity) may increase.
The effect of NSAIDs on the activity of prostaglandins in the kidneys may enhance the nephrotoxicity of cyclosporine.
There are isolated reports of the occurrence of seizures in patients taking NSAIDs and quinolone antibacterial drugs simultaneously.
How to take, course of administration and dosage
For adults, the recommended starting dose is 100-150 mg/day. In relatively mild cases of the disease, as well as for long-term therapy, 75-100 mg/day is sufficient. Frequency of application - 2-3 times. To relieve night pain or morning stiffness, Voltaren is prescribed in suppositories before bedtime, in addition to taking the drug in tablet form during the day; in this case, the total daily dose should not exceed 150 mg.
For primary dysmenorrhea, the daily dose is selected individually; usually it is 50-150 mg. The initial dose should be 50-100 mg; if necessary, over several menstrual cycles it can be increased to 150 mg/day. Treatment should begin when the first symptoms appear. Depending on the dynamics of clinical symptoms, treatment can be continued for several days.
For a migraine attack, the initial dose is 100 mg. The drug is prescribed at the first symptoms of an approaching attack. If necessary, on the same day you can additionally apply Voltaren in suppositories at a dose of up to 100 mg. If it is necessary to continue treatment in subsequent days, the daily dose of the drug should not exceed 150 mg (in several administrations).
Children weighing 25 kg or more are prescribed the drug at a dose of 0.5-2 mg/kg body weight/day (the daily dose, depending on the severity of the disease, should be divided into 2-3 single doses). For the treatment of juvenile rheumatoid arthritis, the daily dose can be increased to a maximum of 3 mg/kg (in several administrations).
The use of 50 mg and 100 mg suppositories in children is not recommended.
Special instructions
During the use of Voltaren, careful medical supervision is necessary for those patients who have complaints indicating gastrointestinal diseases; having a history of ulcerative lesions of the stomach or intestines; those suffering from ulcerative colitis or Crohn's disease, as well as those with impaired liver function.
During the use of Voltaren, as well as other NSAIDs, the level of one or more liver enzymes may increase. Therefore, during long-term therapy with Voltaren, monitoring of liver function is indicated as a precautionary measure. If abnormalities in liver function parameters persist or worsen, or if clinical manifestations of liver disease or other symptoms occur (for example, eosinophilia, rash, etc.), Voltaren should be discontinued. It should be borne in mind that hepatitis during the use of Voltaren can occur without prodromal phenomena.
Caution is necessary when prescribing Voltaren to patients with hepatic porphyria, because the drug can provoke attacks of porphyria.
Since prostaglandins play an important role in maintaining renal blood flow, special caution is required when treating patients with impaired cardiac or renal function, patients receiving diuretics, as well as patients who have a significant decrease in circulating blood plasma volume of any etiology, for example, in the period before and after major surgical interventions. In these cases, monitoring of renal function is recommended as a precautionary measure during the use of Voltaren. Discontinuation of the drug usually results in renal function returning to baseline levels. Caution should be exercised when using Voltaren in elderly patients. This is especially true in frail or low-weight elderly people; they are recommended to prescribe the drug at the minimum effective dose.
During the use of Voltaren, gastrointestinal bleeding may occur (for the first time or repeatedly) or ulceration/perforation of the gastrointestinal tract may develop, accompanied or not accompanied by precursor symptoms. More serious consequences of these complications may occur in older patients. In those rare cases where these complications develop in patients receiving Voltaren, the drug should be discontinued.
When using Voltaren for the first time, as well as other NSAIDs, in rare cases allergic reactions may develop, including anaphylactic and anaphylactoid reactions. Voltaren, due to its pharmacodynamic properties, can mask the manifestations of infectious diseases. Voltaren, like other NSAIDs, may temporarily inhibit platelet aggregation. Therefore, in patients with hemostasis disorders, careful monitoring of relevant laboratory parameters is necessary.
With long-term use of Voltaren, like other NSAIDs, systematic monitoring of peripheral blood patterns is indicated.
Release form
Suppositories
Storage conditions
At a temperature not exceeding 30 °C
Best before date
3 years
Active substance
Diclofenac
Conditions for dispensing from pharmacies
On prescription
Dosage form
rectal suppositories
Purpose
Pregnant women 1st and 2nd trimester as prescribed by a doctor, For adults as prescribed by a doctor
Indications
Adnexitis, Gout, Osteoarthritis, Sciatica, Arthrosis and arthritis, Tendon inflammation, Rheumatoid arthritis, Periarthritis, Swelling after injuries and operations, Bursitis, Lumbago
Barcode and weight
Barcode: 7680392549054 Weight: 0.033 kg
Description of the drug VOLTAREN® for systemic use
The dose is selected individually; it is recommended to use the drug in the minimum effective dose, with the shortest possible treatment period.
For oral and rectal use
Adults
When taken orally in the form of tablets of regular duration or rectally in the form of suppositories, the recommended initial dose is 100-150 mg/day. In relatively mild cases of the disease, as well as for long-term therapy, 75-100 mg/day is sufficient. The daily dose should be divided into several doses.
When taken in the form of extended-release tablets, the recommended initial dose is 100 mg 1 time / day. The same daily dose is used for moderately severe symptoms, as well as for long-term therapy. In cases where the symptoms of the disease are most pronounced at night or in the morning, it is advisable to take extended-release tablets at night.
To relieve night pain or morning stiffness
in addition to taking the drug during the day, diclofenac is prescribed in the form of rectal suppositories before bedtime; in this case, the total daily dose should not exceed 150 mg.
With primary dysmenorrhea
the daily dose is selected individually; usually it is 50-150 mg. The initial dose should be 50-100 mg; if necessary, over several menstrual cycles it can be increased to 150 mg/day. The drug should be started when the first symptoms appear. Depending on the dynamics of clinical symptoms, treatment can be continued for several days.
In elderly patients (65 years and older)
no adjustment of the initial dose is required.
In weakened patients, patients with low body weight
It is recommended to adhere to the minimum dose.
The drug should be used with particular caution in patients with diseases of the cardiovascular system (including uncontrolled arterial hypertension) or a high risk of developing cardiovascular diseases
. If long-term therapy (more than 4 weeks) is necessary in such patients, the drug should be used in a daily dose not exceeding 100 mg.
Children aged 1 year and older
The drug is prescribed in a dose of 0.5-2 mg/kg body weight/day (in 2-3 doses, depending on the severity of the disease). For the treatment of rheumatoid arthritis
the daily dose can be maximally increased to 3 mg/kg (in several doses). The maximum daily dose is 150 mg.
The drug in the form of extended-release tablets should not be used in children and adolescents under the age of 18 years.
For parenteral use
Adults
Injected deep into the / m. Single dose - 75 mg. If necessary, repeated administration is possible, but not earlier than after 12 hours.
Duration of use is no more than 2 days, if necessary, then switch to oral or rectal use of diclofenac.
In severe cases (for example, with colic), as an exception, 2 injections of 75 mg each can be given, with an interval of several hours (the second injection should be carried out in the opposite gluteal region). Alternatively, IM administration once a day (75 mg) can be combined with diclofenac in other dosage forms (tablets, rectal suppositories), and the total daily dose should not exceed 150 mg.
For migraine attacks
Diclofenac is recommended to be administered as early as possible after the onset of an attack, IM at a dose of 75 mg, followed by the use of suppositories at a dose of up to 100 mg on the same day, if required. The total daily dose should not exceed 175 mg on the first day.
In elderly patients (65 years and older)
no adjustment of the initial dose is required. In weakened patients and patients with low body weight, it is recommended to adhere to the minimum dose.
The drug should be used with particular caution in patients with diseases of the cardiovascular system (including uncontrolled arterial hypertension) or a high risk of developing cardiovascular diseases
. If long-term therapy (more than 4 weeks) is necessary in such patients, the drug should be used in a daily dose not exceeding 100 mg.
Children and teenagers under 18 years of age
Diclofenac should not be used intramuscularly in children and adolescents under 18 years of age due to the difficulty of dosing the drug.
Voltaren, 30 pcs., 25 mg, enteric-coated tablets
Gastrointestinal lesions
When using diclofenac, like other NSAIDs, phenomena such as bleeding or ulceration/perforation of the gastrointestinal tract, in some cases with fatal outcome, were observed. These phenomena may occur at any time when using these drugs with or without previous symptoms or a history of serious gastrointestinal diseases. In older patients, such complications can have serious consequences. If patients receiving Voltaren® develop bleeding or gastrointestinal ulceration, the drug should be discontinued.
To reduce the risk of toxic effects on the gastrointestinal tract in patients with ulcerative lesions of the gastrointestinal tract, especially those complicated by bleeding or perforation in history, as well as in elderly patients, the drug should be used in the minimum effective dose.
In patients with an increased risk of developing gastrointestinal complications, as well as in patients receiving therapy with low doses of acetylsalicylic acid, gastroprotectors (proton pump inhibitors or misoprostol) or other medications should be used during drug therapy to reduce the risk of undesirable effects on the gastrointestinal tract.
Patients with a history of gastrointestinal lesions, especially the elderly, should report all abdominal symptoms to the doctor.
Patients with bronchial asthma
Exacerbation of asthma (NSAID intolerance/NSAID-induced asthma), angioedema and urticaria are most often observed in patients with bronchial asthma, seasonal allergic rhinitis, nasal polyps, chronic obstructive pulmonary disease or chronic infectious diseases of the respiratory tract (especially those associated with allergic rhinitis). rhinitis-like symptoms). In this group of patients, as well as in patients with allergies to other drugs (skin rash and itching or urticaria), special caution should be observed when using the drug Voltaren® (preparedness for resuscitation measures).
Skin reactions
Serious dermatological reactions such as exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, in some cases fatal, have been reported very rarely with the use of diclofenac. The highest risk and incidence of severe dermatological reactions were observed in the first month of treatment with diclofenac. If a patient receiving Voltaren® develops the first signs of a skin rash, damage to the mucous membranes or other symptoms of hypersensitivity, the drug should be discontinued.
In rare cases, when using Voltaren®, like other NSAIDs, anaphylactic/anaphylactoid reactions may develop in patients who have not previously received diclofenac.
Effects on the liver
Since during the period of use of the drug Voltaren® there may be an increase in the activity of one or more “liver” enzymes, monitoring of liver function is indicated as a precautionary measure during long-term therapy with the drug. If liver dysfunction persists and progresses or signs of liver disease or other symptoms occur (for example, eosinophilia, rash, etc.), the drug should be discontinued. It should be borne in mind that hepatitis during the use of the drug Voltaren® can develop without prodromal phenomena.
Effects on the kidneys
During therapy with Voltaren®, it is recommended to monitor renal function in patients with hypertension, impaired cardiac or renal function, elderly patients, patients receiving diuretics or other drugs that affect renal function, as well as in patients with a significant decrease in the volume of extracellular fluid of any etiology, for example, during the period before and after major surgical interventions. After cessation of drug therapy, normalization of renal function indicators to initial values is usually observed.
Effects on the cardiovascular system
Therapy with NSAIDs, including diclofenac, particularly long-term and high-dose therapy, may be associated with a small increased risk of serious cardiovascular thrombotic events (including myocardial infarction and stroke).
In patients with diseases of the cardiovascular system and a high risk of developing diseases of the cardiovascular system (for example, with arterial hypertension, hyperlipidemia, diabetes mellitus, smokers), the drug should be used with extreme caution, at the lowest effective dose for the shortest possible duration of treatment, since the risk of thrombotic complications increases with increasing dose and duration of treatment. With long-term therapy (more than 4 weeks), the daily dose of diclofenac in such patients should not exceed 100 mg. The effectiveness of treatment and the patient's need for symptomatic therapy should be periodically assessed, especially in cases where its duration is more than 4 weeks. When the first symptoms of thrombotic disorders appear (for example, chest pain, feeling short of breath, weakness, speech impairment), the patient should immediately seek medical help.
Impact on the hematopoietic system
The drug Voltaren® may temporarily inhibit platelet aggregation, therefore, in patients with hemostasis disorders, it is necessary to carefully monitor relevant laboratory parameters.
With long-term use of the drug Voltaren®, it is recommended to conduct regular clinical tests of peripheral blood.
Masking signs of an infectious process
The anti-inflammatory effect of the drug Voltaren® may complicate the diagnosis of infectious processes.
Use simultaneously with other NSAIDs
Voltaren® should not be used concomitantly with other NSAIDs, including selective COX-2 inhibitors due to the risk of adverse events.
Voltaren gel for back pain, muscles and joints, 2%, 100 g
Manufacturer
Novartis Pharma Stein AG, Switzerland
Briefly about the product
Voltaren Emulgel is intended for pain in the joints, back, muscles, as well as inflammation and swelling of soft tissues and joints. Voltaren Emulgel has a triple effect! 1: against pain 2: against inflammation* 3: to speed up recovery** The active substance diclofenac is a non-steroidal anti-inflammatory drug with pronounced analgesic and anti-inflammatory properties, penetrates deep into the skin, acting on both pain and its cause - inflammation. * * Instructions for medical use, RU No P N016030/01 dated 09.09.2009 ** Limit. Musculoskeletal disorders. 2013, 14:250. Compared to using placebo.
Compound
100 g of gel contains:
Active substances:
Diclofenac diethylamine - 2.32 g, which corresponds to the content of diclofenac sodium 2 g.
Excipients:
Carbomers* - 1.1-1.7 g; Cetostearomacrogol - 2 g; Cocoyl caprylocaprate - 2.5 g; Diethylamine* - 0.89-1.37 g; Isopropanol - 17.5 g; Liquid paraffin - 2.5 g; Oleyl alcohol - 0.75 g; Eucalyptus flavoring – 0.1 g; Propylene glycol - 5 g; Butylated hydroxytoluene - 0.02 g; Purified water* - 64.22-65.32 g.
* when using different production equipment and different batch sizes (1000 kg and 2500 kg), the amounts of carbomers, diethyleneamine and purified water may be slightly adjusted within the indicated figures.
pharmachologic effect
NSAIDs for external use. Diclofenac has a pronounced analgesic, anti-inflammatory and antipyretic effect. By indiscriminately inhibiting COX-1 and COX-2, it disrupts the metabolism of arachidonic acid. Voltaren® Emulgel® is used to eliminate pain and inflammation in joints, muscles and ligaments of traumatic or rheumatic origin, helping to reduce pain and swelling associated with the inflammatory process, increasing joint mobility. Thanks to its hydroalcoholic base, Voltaren® Emulgel® has a calming and cooling effect.
Clinical pharmacology
Absorption The amount of diclofenac absorbed through the skin is proportional to the area of the treated surface and depends both on the total dose of the drug applied and on the degree of skin hydration. After applying Voltaren® Emulgel®, gel for external use 2% (2 applications per day) to a skin surface area of 400 cm2, the concentration of the active substance in plasma corresponds to its concentration when using 1% diclofenac gel (4 applications per day). On day 7, the relative bioavailability of the drug (AUC ratio) is 4.5% (for an equivalent dose of diclofenac sodium salt). When wearing a moisture-permeable dressing, suction did not change. Distribution When applying the drug to the area of the affected joint, the concentration of diclofenac in plasma, synovial membrane and synovial fluid was determined. Cmax in plasma was approximately 100 times lower than after oral administration of the same amount of diclofenac. The binding of diclofenac to plasma proteins is 99.7%, mainly with albumin (99.4%). Diclofenac is preferentially distributed and retained deep in tissues prone to inflammation, such as joints, where its concentration is 20 times higher than in plasma. Metabolism The metabolism of diclofenac is carried out partly by glucuronidation of the unchanged molecule, but mainly through single and multiple hydroxylation, which leads to the formation of several phenolic metabolites, most of which are converted to glucuronide conjugates. Two phenolic metabolites are biologically active, but to a much lesser extent than diclofenac. Elimination The total systemic plasma clearance of diclofenac is 263±56 ml/min. The final T1/2 is 1-2 hours. The T1/2 of metabolites, including two pharmacologically active ones, is also short-lived and is 1-3 hours. One of the metabolites (3′-hydroxy-4′-methoxydiclofenac) has a longer T1/2, however, this metabolite is completely inactive. Most of diclofenac and its metabolites are excreted in the urine.
Indications
- Back pain due to inflammatory and degenerative diseases of the spine (sciatica, osteoarthritis, lumbago, sciatica);
- pain in the joints (including finger joints, knees) due to rheumatoid arthritis, osteoarthritis;
- muscle pain (due to sprains, strains, bruises, injuries);
- inflammation and swelling of soft tissues and joints due to injuries and rheumatic diseases (tenosynovitis, bursitis, lesions of periarticular tissues, wrist syndrome).
Use during pregnancy and breastfeeding
Due to the lack of data on the use of the drug Voltaren® Emulgel® during pregnancy, the use of the drug in the first and second trimesters of pregnancy is recommended only as prescribed by a doctor, weighing the benefits for the mother and the risk for the fetus. The drug is contraindicated in the third trimester of pregnancy due to the possibility of decreased uterine tone, impaired fetal renal function with subsequent development of oligohydramnios and/or premature closure of the fetal ductus arteriosus. Due to the lack of data on the release of the active substance of Voltaren® Emulgel® into breast milk, the drug is not recommended for use during breastfeeding. If it is still necessary to use the drug, it should not be applied to the mammary glands or large surface areas of the skin and should not be used for a long time. There are no data on the effect of the drug on fertility.
Contraindications
Hypersensitivity to diclofenac or other components of the drug; tendency to develop attacks of bronchial asthma, skin rashes or acute rhinitis when using acetylsalicylic acid or other NSAIDs; violation of the integrity of the skin at the intended site of application; III trimester of pregnancy; lactation period (breastfeeding); children up to 12 years of age. The drug should be prescribed with caution for hepatic porphyria (in the acute phase), erosive and ulcerative lesions of the gastrointestinal tract, severe liver and kidney dysfunction, chronic heart failure, bronchial asthma, as well as in the first and second trimesters of pregnancy and elderly patients.
Side effects
Determination of the frequency of adverse reactions: very often (≥1/10), often (≥1/100, <1/10), infrequently (≥1/1000, <1/100), rarely (≥1/10,000, <1 /1000), very rarely (<1/10,000), including isolated reports. Infectious and parasitic diseases: very rarely: pustular rash. From the immune system: very rarely - hypersensitivity reactions (including urticaria), angioedema. From the respiratory system: very rarely - asthma. From the skin and subcutaneous tissues: often - dermatitis (including contact dermatitis), rash, erythema, eczema, itching; rarely - bullous dermatitis; very rarely - photosensitivity reactions. If any of the above adverse reactions worsen, or the patient notices any other adverse reactions, the doctor should be informed.
Interaction
Voltaren® Emulgel® may enhance the effect of drugs that cause photosensitivity. Clinically significant interactions with other drugs have not been described.
How to take, course of administration and dosage
The drug is used externally. For adults and children over 12 years of age, the drug is applied to the skin 2 times a day (every 12 hours: preferably morning and evening), lightly rubbing into the skin. The required amount of the drug depends on the size of the painful area. A single dose of the drug - 2-4 g (which is comparable in volume to the size of a cherry or walnut) - is enough to treat an area of 400-800 cm2. If your hands are not the area where pain is localized, then after applying the drug they should be washed. The duration of treatment depends on the indications and the observed effect. The gel should not be used for more than 14 days for post-traumatic inflammation and rheumatic diseases of soft tissues without a doctor’s recommendation. If after 7 days of use the therapeutic effect is not observed or the condition worsens, the patient should consult a doctor. To remove the protective membrane, use the screw cap as a key (the recess with protrusions on the outside of the cap). Align the indentation on the outside of the cap with the shaped protective membrane of the tube and turn. The membrane should separate from the tube. The tubes can have either a regular cap (round shape) or an innovative cap (triangular shape), which is especially convenient for use when the mobility of the hand joints is limited due to osteoarthritis or other joint diseases or injuries.
Overdose
Due to the low systemic absorption when applying the gel, overdose is unlikely. Symptoms: accidental ingestion may cause systemic adverse reactions. Treatment of overdose due to accidental ingestion: gastric lavage, induction of vomiting, activated charcoal, symptomatic therapy. Dialysis and forced diuresis are not effective due to the high degree of binding of diclofenac to plasma proteins (about 99%).
Description
Gel for external use 2% is homogeneous, creamy, white to white with a yellowish tint.
Special instructions
Voltaren® Emulgel® should be applied only to intact skin, avoiding contact with open wounds. The drug should not come into contact with the eyes and mucous membranes. After applying the gel for external use 1%, you should not apply an occlusive dressing. After applying the gel for external use 2%, a bandage may be applied, but airtight occlusive dressings should not be applied. If a skin rash develops after application of the drug, its use should be discontinued. This medicine contains propylene glycol, which may cause mild local irritation in some people. It also contains butylated hydroxytoluene, which may cause local skin reactions (eg contact dermatitis) or irritation of the eyes and mucous membranes.
Release form
100 g - laminated tubes (1) - cardboard packs.
Storage conditions
The drug should be stored out of the reach of children at a temperature not exceeding 30°C.
Best before date
3 years
Active substance
Diclofenac
Dosage form
gel for external use
Purpose
For adults, Pregnant women in the 1st and 2nd trimester as prescribed by a doctor, Children over 12 years old
Indications
Swelling after injuries and operations, Bursitis, Gout, Rheumatoid arthritis, Periarthritis, Osteoarthritis, Arthrosis and arthritis, Sciatica, Lumbago, Tendon inflammation, Adnexitis
Barcode and weight
Barcode: 4607045192439, 4602233007212, - Weight: 0.130 kg
